Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development

IF 8.7 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Molecular Aspects of Medicine Pub Date : 2023-12-26 DOI:10.1016/j.mam.2023.101239

Namrata Gautam , Ganesan Ramamoorthi , Nicholas Champion , Hyo S. Han , Brian J. Czerniecki

{"title":"Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development","authors":"Namrata Gautam , Ganesan Ramamoorthi , Nicholas Champion , Hyo S. Han , Brian J. Czerniecki","doi":"10.1016/j.mam.2023.101239","DOIUrl":null,"url":null,"abstract":"<div><p>Breast cancer is a heterogeneous disease and is the most prevalent cancer in women. According to the U.S breast cancer statistics, about 1 in every 8 women develop an invasive form of breast cancer during their lifetime. Immunotherapy has been a significant advancement in the treatment of cancer with multiple studies reporting favourable patient outcomes by modulating the immune response to cancer cells. Here, we review the significance of dendritic cell vaccines in treating breast cancer patients. We discuss the involvement of dendritic cells and oncodrivers in breast tumorigenesis, highlighting the rationale for targeting oncodrivers and neoantigens using dendritic cell vaccine therapy. We review different dendritic cell subsets and maturation states previously used to develop vaccines and suggest the use of DC vaccines for breast cancer prevention. Further, we highlight that the intratumoral delivery of type 1 dendritic cell vaccines in breast cancer patients activates tumor antigen-specific CD4<sup>+</sup><span> T helper cell type 1 (Th1) cells, promoting an anti-tumorigenic immune response while concurrently blocking pro-tumorigenic responses. In summary, this review provides an overview of the current state of dendritic cell vaccines in breast cancer highlighting the challenges and considerations necessary for an efficient dendritic cell vaccine design in interrupting breast cancer development.</span></p></div>","PeriodicalId":49798,"journal":{"name":"Molecular Aspects of Medicine","volume":"95 ","pages":"Article 101239"},"PeriodicalIF":8.7000,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Aspects of Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0098299723000791","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Breast cancer is a heterogeneous disease and is the most prevalent cancer in women. According to the U.S breast cancer statistics, about 1 in every 8 women develop an invasive form of breast cancer during their lifetime. Immunotherapy has been a significant advancement in the treatment of cancer with multiple studies reporting favourable patient outcomes by modulating the immune response to cancer cells. Here, we review the significance of dendritic cell vaccines in treating breast cancer patients. We discuss the involvement of dendritic cells and oncodrivers in breast tumorigenesis, highlighting the rationale for targeting oncodrivers and neoantigens using dendritic cell vaccine therapy. We review different dendritic cell subsets and maturation states previously used to develop vaccines and suggest the use of DC vaccines for breast cancer prevention. Further, we highlight that the intratumoral delivery of type 1 dendritic cell vaccines in breast cancer patients activates tumor antigen-specific CD4⁺ T helper cell type 1 (Th1) cells, promoting an anti-tumorigenic immune response while concurrently blocking pro-tumorigenic responses. In summary, this review provides an overview of the current state of dendritic cell vaccines in breast cancer highlighting the challenges and considerations necessary for an efficient dendritic cell vaccine design in interrupting breast cancer development.

查看原文本刊更多论文

回顾树突状细胞疫苗在阻断乳腺癌发展中的重要作用。

乳腺癌是一种多发性疾病，也是女性最常见的癌症。根据美国乳腺癌统计数据，每 8 名妇女中就有 1 人在一生中罹患浸润性乳腺癌。免疫疗法在治疗癌症方面取得了重大进展，多项研究报告称，通过调节癌细胞的免疫反应，可为患者带来良好的治疗效果。在此，我们回顾了树突状细胞疫苗在治疗乳腺癌患者方面的意义。我们讨论了树突状细胞和肿瘤驱动因子参与乳腺肿瘤发生的情况，强调了使用树突状细胞疫苗疗法靶向肿瘤驱动因子和新抗原的合理性。我们回顾了以前用于开发疫苗的不同树突状细胞亚群和成熟状态，并建议将树突状细胞疫苗用于乳腺癌预防。此外，我们还强调，乳腺癌患者瘤内注射 1 型树突状细胞疫苗可激活肿瘤抗原特异性 CD4+ T 辅助细胞 1 型（Th1）细胞，促进抗肿瘤免疫反应，同时阻断促肿瘤反应。总之，本综述概述了树突状细胞疫苗在乳腺癌中的应用现状，强调了设计有效的树突状细胞疫苗以阻断乳腺癌发展所面临的挑战和需要考虑的因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Aspects of Medicine 医学-生化与分子生物学

CiteScore

18.20

自引率

0.00%

发文量

审稿时长

55 days

期刊介绍： Molecular Aspects of Medicine is a review journal that serves as an official publication of the International Union of Biochemistry and Molecular Biology. It caters to physicians and biomedical scientists and aims to bridge the gap between these two fields. The journal encourages practicing clinical scientists to contribute by providing extended reviews on the molecular aspects of a specific medical field. These articles are written in a way that appeals to both doctors who may struggle with basic science and basic scientists who may have limited awareness of clinical practice issues. The journal covers a wide range of medical topics to showcase the molecular insights gained from basic science and highlight the challenging problems that medicine presents to the scientific community.